ReviewThe world journal of men's health2025
Liquid Biomarkers in Prostate Cancer Diagnosis: Current Status and Emerging Prospects.
Review in The world journal of men's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Urinary Biomarkers in Urological Oncology: From Biological Origin to Clinical Decision-Making-A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- A serum-clinical composite model for prostate cancer diagnosis: multicenter validation and CRISPR/Cas13a-based detection.The journal of liquid biopsy · 2026Article
- Plasmonic Nanoarray Biosensors for Non-Invasive Cancer Diagnostics.Biosensors · 2026Review
- Stem Cell-Delivered Cytosine Deaminase/5-Fluorocytosine and TRAIL Gene Therapy for Castration-Resistant Prostate Cancer: Translational Synthesis and First-in-Human Trial Concept.International journal of molecular sciences · 2026Review
- Microsensors for a Quick Detection of Tissue Functional Age and Precision Medicine.Physiological research · 2026Article
- An artificial intelligence model integrating clinico-laboratory data and single nucleotide polymorphism-based genomic risk for prostate cancer diagnosis in Korean men.Investigative and clinical urology · 2026Article
- Utility of the PROSTest, a Novel Blood-Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease.The Prostate · 2026Article
- Urine-based PSMA detection for noninvasive prostate cancer diagnosis: recent advances, translational challenges, and future perspectives.Frontiers in oncology · 2026Review
- PROSTest, a Multigene Liquid Biopsy Signature, Effectively Stratifies Patients With High PSA for Prostate Biopsy.The Prostate · 2026Article
- Article
- Leveraging Synergy: A Review of the Therapeutic Potential of SN-38 and Immune Checkpoint Blockade in Breast and Prostate Cancer Treatment.Journal of personalized medicine · 2025Review
- Blood and urine-based biomarkers in prostate cancer: Current advances, clinical applications, and future directions.The journal of liquid biopsy · 2025Review
- METCAM/MUC18 is a Biomarker and Therapeutic Target for Prostate Cancer.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- A machine learning-based screening model for the early detection of prostate cancer developed using serum microRNA data from a mixed cohort of 8,741 participants.Discover oncology · 2025Article
- Transforming Prostate Cancer Care: Innovations in Diagnosis, Treatment, and Future Directions.International journal of molecular sciences · 2025Review
- Overdiagnosis and Overtreatment in Prostate Cancer.Diseases (Basel, Switzerland) · 2025Review
- Improvement of the sensitivity of circulating tumor DNA-based liquid biopsy: current approaches and future perspectives.Exploration of targeted anti-tumor therapy · 2025Review
- Advancements in Biomarkers of Prostate Cancer: A Review.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Prostate cancer (PCa) is a major health concern that necessitates appropriate diagnostic approaches for timely intervention. This review critically evaluates the role of liquid biopsy techniques, focusing on blood- and urine-based biomarkers, in overcoming the limitations of conventional diagnostic methods. The 4Kscore test and Prostate Health Index have demonstrated efficacy in distinguishing PCa from benign conditions. Urinary biomarker tests such as PCa antigen 3, MyProstateScore, SelectMDx, and ExoDx Prostate IntelliScore test have revolutionized risk stratification and minimized unnecessary biopsies. Emerging biomarkers, including non-coding RNAs, circulating tumor DNA, and prostate-specific antigen (PSA) glycosylation, offer valuable insights into PCa biology, enabling personalized treatment strategies. Advancements in non-invasive liquid biomarkers for PCa diagnosis may facilitate the stratification of patients and avoid unnecessary biopsies, particularly when PSA is in the gray area of 4 to 10 ng/mL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.